Navigation Links
Novel Cancer Immunotherapy set to enter Clinical Trials
Date:4/16/2013

LAWRENCEBURG, Ind., April 16, 2013 /PRNewswire/ -- PDS Biotechnology Corporation today presented a summary of the company's preclinical data on its lead cancer immunotherapy PDS0101 at the World Vaccine Congress in Washington DC.  The product is based on the company's ground-breaking and proprietary Versamune™ nanotechnology vaccine platform.  PDS Biotechnology also announced that the company's Investigational New Drug (IND) application had been granted by the FDA allowing PDS0101 to be evaluated in human patients.

PDS0101 is a first-in-class immunotherapy being developed to treat cancers and diseases caused by infection with the human papillomavirus such as cervical cancer, head and neck cancer and cervical intraepithelial neoplasia.  Dr. Frank Bedu-Addo , President and CEO presented the highly promising preclinical efficacy and safety data demonstrating eradication of the tumors without any of the safety drawbacks typical of the current immunotherapy technologies.  PDS0101 is designed to prime the immune system to recruit cells of the body's own immune system to specifically recognize, target and kill the cancer cells.  PDS0101 is also designed to reduce the population of certain immune suppressive cells which prevent our immune systems from detecting and attacking the cancer cells.  "Should the preclinical results be replicated in the clinical setting, this will be a giant leap forward in the development of safe and effective cancer therapies," said Frank Bedu-Addo .

Versamune™ is a nanotechnology-based immune modulating technology which acts by a novel mechanism to prime and activate the immune system to recognize specific diseased cells and disease causing agents.   The technology is unique in its multiple-mode-of-action enabling simple and effective disease-targeting vaccines and immunotherapies to be
'/>"/>

SOURCE PDS Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Data on SEEKs Novel Immunotherapy for HIV Published in Virology Journal
2. TransCelerate BioPharma Inc. Grows, Strengthens Novel Effort to Accelerate Drug Development
3. NewGen Therapeutics Presents Data on NT-113, A Novel Pan-ErbB Inhibitor, at American Association of Cancer Research
4. scPharmaceuticals LLC Announces Strategic Partnership with Sensile Medical to Develop Novel Heart Failure Treatment Aimed to Reduce Readmission Rates
5. X-BODY Announces Multi-Million Dollar Development Alliance With Jiangsu Hengrui Medicine Co., Ltd., A Leading Pharmaceutical Company In China, To Develop Novel Therapeutic Antibodies For AMD
6. NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer
7. NeuroVive Acquires Highly Potent, Novel Cyclophilin Inhibitors From Biotica
8. A Novel Oral Anticoagulant is Planned to be Developed for Patients with Prosthetic Heart Valves or Chronic Renal Dysfunction
9. Receptos Determines Novel GPCR Structure, Achieves Key Milestone in Collaboration with Ono Pharmaceuticals
10. Alzheimers Drug Discovery Foundation Awards Grant To CohBar to Develop A Novel Peptide Therapeutic For Alzheimers Disease
11. West Announces the Commercial Introduction of a Novel Intradermal Adapter for Disposable Syringes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014  RXi Pharmaceuticals ... company focused on discovering, developing and commercializing innovative ... technologies, today announced completion of enrollment in its first ... the 3-month observations confirmed the 1-month findings that ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... addition of the "MEMS Gyroscopes Analog Devices ... report to their offering. ... for tactical grade applications made a lot of ... of reliability. They are now accepted in high-reliability ...
(Date:12/15/2014)... 15, 2014 BerGenBio AS, a ... drug resistant cancers, today announces that it has raised ... from new and existing investors. BerGenBio will ... development of its pipeline of innovative cancer therapeutics, in ... drug candidate, BGB324, a first-in-class selective Axl kinase inhibitor, ...
Breaking Medicine Technology:RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2BerGenBio Completes NOK90 Million Fundraising 2
(Date:12/19/2014)... Norton HealthDay Reporter THURSDAY, ... who were exposed to high levels of air pollution late ... a U.S. study suggests. Researchers found that of nearly ... those exposed to the most air pollution during pregnancy were ... autism. And exposure during the third trimester, specifically, showed the ...
(Date:12/19/2014)... Dec. 18, 2014 (HealthDay News) -- Prostaglandin analogue eye ... significantly reduce the risk of vision loss in patients ... British researchers led by David Garway-Heath, of the Moorfields ... tracked outcomes for more than 500 people newly diagnosed ... the disease and one of the leading causes of ...
(Date:12/17/2014)... Myo Nwe is the co-author of a new weight loss ... of the Ace Medical Weight Loss Center in Rock Hill, ... at the industry of weight loss, and how several fad ... in television shows, however, she says the topic of obesity ... for basic laughs, which she believes impacts whether Americans view ...
(Date:12/17/2014)... HeartMath® Inc., recognized as one of ... variability (HRV), heart coherence and the physiology of ... and algorithms to chipset manufacturers and consumer electronics ... to offer its HRV solutions, tap into its ... its normative HRV databases and algorithms for developing ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 No matter ... been able to eradicate the head louse parasite—a common ... for parents. Each year between six and twelve million ... the Miami-based lice removal treatment company comes to the ... and environmentally friendly. With its track record of customer ...
Breaking Medicine News(10 mins):Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3Health News:Study Supports Benefit of Widely Used Glaucoma Drug 2Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2
... Jerry Posakony, scientist at the Department of Energy,s Pacific ... Association of Engineering Societies for his pioneering contributions to ... evaluation technologies. AAES has awarded the John Fritz ... engineer and 15th president of the American Society of ...
... finds 3 percent of those who get something lodged in ... Although the number of young children who choke after swallowing ... when that happens is real, the latest research indicates. , ... study author Dr. Rahul K. Shah, a pediatric otolaryngologist with ...
... researchers in the University of Alabama at Birmingham (UAB) ... identify potential dangers on playgrounds and in gymnasiums and ... The tools consist of two checklists that ... facilities and equipment on playgrounds and in gymnasiums. The ...
... The ... 146 medical schools and schools of osteopathic medicine nationwide, jumping from 32nd in 2005. ... New York (Vocus) April 19, 2010 -- ... 18th out of 146 medical schools and schools of osteopathic medicine nationwide, jumping from 32nd in ...
... ... leadership through technology innovation and improved usability. , ... (PRWEB) April 19, 2010 -- FileTrail, ... announced the release of FileTrail 4.0. This new release extends the company,s leadership ...
... ... the Easy Water system in Austin, Texas. The Easy Water system is a revolutionary alternative ... as calcium and magnesium in your water, without them resulting in hard water buildup. ... Austin, Texas -- 1st Plumbing ...
Cached Medicine News:Health News:Fatal Choking a Real Risk Among Toddlers 2Health News:Fatal Choking a Real Risk Among Toddlers 3Health News:Free UAB service to help parents advocate for safer playgrounds, gyms 2Health News:Mount Sinai School of Medicine Ranked in the Top 20 Best Medical Schools by US News & World Report 2Health News:Newest Release of FileTrail Sets New Standard in Global Physical Records Management and File Tracking 2Health News:Newest Release of FileTrail Sets New Standard in Global Physical Records Management and File Tracking 3Health News:1st Plumbing Services Selected to be Exclusive Dealer in Austin, Texas for Installation of Easy Water No-Salt Water Conditioning System 2Health News:1st Plumbing Services Selected to be Exclusive Dealer in Austin, Texas for Installation of Easy Water No-Salt Water Conditioning System 3
Foreign body spud very thin, lightly curved and rounded tip....
... premium high water content ... permeability. Standard one fit ... the following therapeutic conditions: ... bullous keratopathy, recurrent ulcers, ...
Bandage lenses....
Guthrie skin hook with 2 prongs....
Medicine Products: